- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2023 · program · P30
Understanding the impact of an EHR-integrated hereditary cancer risk assessment application on patient-provider communication
Laurie Hollis Glimcher · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2025 · research · Innovative Project Award
Immunogenicity in Mitochondrial Cardiomyopathies
Pere Puigserver · Dana-Farber Cancer Institute · funded by American Heart Association
2023–2027 · grant · BCRP
Turning Breast Cancer Cells Against Themselves as the Next-Generation Immunotherapy
Ming-Ru Wu · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2023–2025 · fellowship · Postdoctoral Fellowship
Post-translational regulations of Znf423 that initiate differentiation and thermogenesis in brown and beige adipocytes
Jingjing Chen · Dana-Farber Cancer Institute · funded by American Heart Association
2023–2025 · research · R37
Molecular origins and evolution to chemoresistance in germ cell tumors
Eliezer M Van Allen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2026 · cooperative agreement · U24
Supplement: Enhancing Community Contributions to Bioconductor With Build System Containerization and a GPU for Testing
Vincent James Carey · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Mitoribosome protein translation signaling and survival mechanisms
Pere Puigserver · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Disparities in Clinical Trial Enrollment among Adolescents and Young Adults with Cancer
Jennifer W Mack · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Gynecologic and Gastrointestinal Cancers - a Multi-Site Randomized Controlled Trial
Alexi A Wright · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2025 · research · R21
Combined bromodomain and CDK4/6 inhibition in NUT Carcinoma and other solid tumors
Michael L. Cheng · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · cooperative agreement · U54
Radiation Oncology at the Interface of Pediatric Cancer Biology and Data Science
Daphne A. Haas-Kogan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2024 · award
EXPLORING THE ROLE OF SUCCINATE RECEPTOR 1 SIGNALING IN BREAST CANCER PROGRESSION
Evanna Mills · Dana-Farber Cancer Institute · funded by American Cancer Society
2023–2027 · research · R01
Regulatory mechanisms of mitochondrial cristae biogenesis and thermogenic function
Pere Puigserver · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Targeting SHP-1 through a newfound metabolite-regulated cysteine activation site
Edward Thomas Chouchani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2027 · award
Transcription and translation as resistance drivers to BET inhibition
Pratiti Bandopadhayay · Dana-Farber Cancer Institute · funded by American Cancer Society
2023–2026 · research · Research Grant
Targeting the Mitoribosome to Treat Mitochondrial Myopathies
Pere Puigserver · Dana-Farber Cancer Institute · funded by Muscular Dystrophy Association
2023–2028 · research · R01
Molecular mechanisms and therapeutic targeting of activated NRF2 signaling in MiT/TFE translocation renal cell carcinoma
Srinivas Raghavan Viswanathan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Probing the role of somatic X-chromosome alterations in shaping cancer sex differences
Srinivas Raghavan Viswanathan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Consequences of retrotransposition on genome integrity
Kathleen H Burns · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2024 · career development · K99
Defining PRC1.1 as a gatekeeper of lineage plasticity and response to anti-GD2 therapy
Nathaniel Mabe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Molecular mechanisms and therapeutic targeting of activated NRF2 signaling in MiT/TFE translocation renal cell carcinoma
Srinivas Raghavan Viswanathan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases
Mohammad Rashidian · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2025 · career development · K99
Robust and cost-effective computational methods for haplotype-resolved genome assemblies
Haoyu Cheng · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023 · career development · K08
Fast-kinetics approaches to define direct gene-regulatory functions of MYB in leukemia
Maxim Pimkin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · cooperative agreement · U54
Radiation Oncology at the Interface of Pediatric Cancer Biology and Data Science
Daphne A. Haas-Kogan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2026 · grant · KCRP
Mechanisms and Predictors of Adoptive Cytokine-Induced Memorylike NK Cell Therapy in Renal Cell Carcinoma
Toni Choueiri · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2023–2025 · career development · K99
Targeting Menin Protein Stability In AML
Jevon Cutler · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2027 · research · R01
Mechanisms of response and resistance to KRAS inhibition in pancreatic cancer
Andrew James Aguirre · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2025 · grant · PCRP
Defining Androgen Receptor Function and Disease Dependencies in BRCA1/2-Deficient Prostate Cancer
Nicole Traphagen · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2023–2028 · career development · K08
Improving response prediction to neoadjuvant therapy in pancreatic cancer
Harshabad Singh · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2027 · research · R01
Regulatory mechanisms of mitochondrial cristae biogenesis and thermogenic function
Pere Puigserver · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2025 · research · R37
Molecular origins and evolution to chemoresistance in germ cell tumors
Eliezer M Van Allen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2024 · career development · K99
Robust and cost-effective computational methods for haplotype-resolved genome assemblies
Haoyu Cheng · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2026 · grant · OCRP
Drugging the Undruggable: Programming Ovarian Cancer Cells as the Next-Generation Immunotherapy
Ming-Ru Wu · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2023–2027 · research · R37
Liquid biopsy in myeloma to inform outcome and treatment decisions
Jens G Lohr · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2027 · research · R01
Probing functional HIV-1 envelope glycoprotein conformations with novel potent CD4-mimetic compounds
Wayne A. Hendrickson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2026 · fellowship · F32
Targeting the cancer neo-genome for destruction with CRISPR-Cas enzymes
Mitchell L Leibowitz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2025 · research · R21
Combined bromodomain and CDK4/6 inhibition in NUT Carcinoma and other solid tumors
Michael L. Cheng · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2025 · research · R37
Molecular origins and evolution to chemoresistance in germ cell tumors
Eliezer M Van Allen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2024 · research · R37
Liquid biopsy in myeloma to inform outcome and treatment decisions
Jens G Lohr · Dana-Farber Cancer Institute · funded by National Institutes of Health
